Department of Internal Medicine IV, Jena University Hospital, Jena, Germany.
Internistische Gemeinschaftspraxis für Verdauungs- und Stoffwechselkrankheiten Leipzig und Schkeuditz, Leipzig, Germany.
J Crohns Colitis. 2020 Dec 2;14(12):1702-1708. doi: 10.1093/ecco-jcc/jjaa126.
The coronavirus disease 2019 [COVID-19] pandemic is affecting lives worldwide. The influence of inflammatory bowel disease [IBD] medication and IBD itself on COVID-19 is controversial. Additionally, IBD-focused guidance is scarce.
Our aims were to determine COVID-19 prevalence/exposure, perception and information sources, medication compliance, patient behaviour and physician contact among patients with IBD compared with non-IBD controls.
A cross-sectional anonymous survey of patients with IBD [N = 415] at one university IBD clinic and one gastroenterology practice, matched 4:1 with control participants [N = 116], was performed.
Patients with IBD had a high fear of infection. This was more pronounced in patients taking immunosuppressants and it extended to hospitals, private practices and public places, such as supermarkets. IBD patients reported leaving their homes less frequently than their peers without IBD. A total of 90% of patients with IBD reported washing their hands more frequently. Patients taking immunosuppressants were concerned about interactions between medication and COVID-19, whereas patients taking 5-aminosalicylates were not. Nonetheless, 96.4% of patients adhered to continuing their medication. Patients sought guidance primarily from television and internet news sites. Video consultations were found to be a suitable solution for a subset of patients who are young, have a high level of fear and leave their home less frequently than their peers, whereas overall acceptance of video consultations was limited.
Patients with IBD are significantly more affected by the COVID-19 pandemic than their non-IBD peers, but they continue to adhere to their medication regimens. IBD-focused COVID-19 information should be actively conveyed.
2019 年冠状病毒病（COVID-19）大流行正在影响全球各地的人们的生活。炎症性肠病（IBD）药物和 IBD 本身对 COVID-19 的影响存在争议。此外，针对 IBD 的指导意见也很少。
我们的目的是确定与非 IBD 对照相比，IBD 患者中 COVID-19 的患病率/暴露率、认知和信息来源、药物依从性、患者行为和医生接触情况。
对一家大学 IBD 诊所和一家胃肠病学诊所的 IBD 患者（N=415）进行了横断面匿名调查，并与对照组（N=116）进行了 4：1 匹配。
IBD 患者对感染的恐惧程度很高。服用免疫抑制剂的患者更为明显，而且这种恐惧还扩展到了医院、私人诊所和公共场所，如超市。IBD 患者报告称，他们比没有 IBD 的同龄人更频繁地离开家。共有 90%的 IBD 患者报告称他们更频繁地洗手。服用免疫抑制剂的患者担心药物与 COVID-19 之间的相互作用，而服用 5-氨基水杨酸的患者则不担心。尽管如此，96.4%的 IBD 患者仍坚持继续服用药物。患者主要从电视和互联网新闻网站获取指导。视频咨询被发现是一组年轻、恐惧程度高、离家频率低于同龄人患者的合适解决方案，而总体上对视频咨询的接受程度有限。
与非 IBD 同龄人相比，IBD 患者受到 COVID-19 大流行的影响更为显著，但他们仍继续坚持其治疗方案。应积极传达针对 IBD 的 COVID-19 信息。
